MA54089A - Anticorps anti-pd-1 humain et procédés d'utilisation associés - Google Patents

Anticorps anti-pd-1 humain et procédés d'utilisation associés

Info

Publication number
MA54089A
MA54089A MA054089A MA54089A MA54089A MA 54089 A MA54089 A MA 54089A MA 054089 A MA054089 A MA 054089A MA 54089 A MA54089 A MA 54089A MA 54089 A MA54089 A MA 54089A
Authority
MA
Morocco
Prior art keywords
antibodies
methods
human anti
human
Prior art date
Application number
MA054089A
Other languages
English (en)
Inventor
Thierry O Fischmann
Chakravarthy Nachu Narasimhan
Winifred W Prosise
Paul Reichert
Corey Strickland
Yongchao Su
Erika R Walsh
Xiaoyu Yang
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MA54089A publication Critical patent/MA54089A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
    • C30B29/54—Organic compounds
    • C30B29/58—Macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Materials Engineering (AREA)
  • Metallurgy (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA054089A 2018-10-31 2019-10-28 Anticorps anti-pd-1 humain et procédés d'utilisation associés MA54089A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862753615P 2018-10-31 2018-10-31

Publications (1)

Publication Number Publication Date
MA54089A true MA54089A (fr) 2022-02-09

Family

ID=70463443

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054089A MA54089A (fr) 2018-10-31 2019-10-28 Anticorps anti-pd-1 humain et procédés d'utilisation associés

Country Status (11)

Country Link
US (2) US12576159B2 (fr)
EP (1) EP3873941B1 (fr)
JP (1) JP7475341B2 (fr)
KR (1) KR102876292B1 (fr)
CN (2) CN120842406A (fr)
AU (1) AU2019369222B2 (fr)
BR (1) BR112021008122A8 (fr)
CA (1) CA3116592A1 (fr)
MA (1) MA54089A (fr)
MX (1) MX2021004928A (fr)
WO (1) WO2020092233A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021004356A (es) 2018-10-18 2021-05-31 Merck Sharp & Dohme Llc Formulaciones de anticuerpos anti-rsv y metodos de uso de las mismas.
MA54089A (fr) 2018-10-31 2022-02-09 Merck Sharp & Dohme Anticorps anti-pd-1 humain et procédés d'utilisation associés
JP7503056B6 (ja) 2018-11-07 2024-07-16 メルク・シャープ・アンド・ドーム・エルエルシー 抗lag3抗体および抗pd-1抗体の共-製剤
CN113797330A (zh) * 2020-06-11 2021-12-17 三生国健药业(上海)股份有限公司 一种抗pd-1单克隆抗体液体制剂
KR20230053614A (ko) * 2020-07-31 2023-04-21 메사추세츠 인스티튜트 오브 테크놀로지 고체 형태의 폴리펩티드를 포함하는 조성물 및 관련 방법
AU2022212007A1 (en) 2021-01-29 2023-09-07 Merck Sharp & Dohme Llc Compositions of programmed death receptor 1 (pd-1) antibodies and methods of obtaining the compositions thereof
CN113980093B (zh) * 2021-10-25 2024-07-26 河北工业大学 聚合物促进蛋白质类药物结晶的方法及应用
US20260193350A1 (en) * 2022-11-21 2026-07-09 Merck Sharp & Dohme Llc Methods for preparing anti-human pd-1 antibody crystals and methods of use thereof
WO2025085538A1 (fr) * 2023-10-17 2025-04-24 Lanier Biotherapeutics, Inc. Molécules de liaison à l'alarmine et traitement du cancer
KR20260116273A (ko) 2024-09-20 2026-07-28 파라곤 테라퓨틱스, 인크. Pd-1 결합 단백질, vegf 및 pd-1 이중특이적 결합 단백질, 조성물 및 사용 방법

Family Cites Families (248)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4401820A (en) 1981-01-23 1983-08-30 Tanabe Seiyaku Co., Ltd. Process for racemizing optically active α-amino acids or a salt thereof
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
DE68920693T2 (de) 1988-03-30 1995-05-24 Toray Industries Gefriergetrocknete Zusammensetzung, die ein mit Meerrettichperoxydase markiertes Fab'-Fragment eines gegen menschliches Beta-Interferon gerichteten Antikörpers und Trehalose enthält; EIA Kit, der diese Zusammensetzung enthält.
JPH03504605A (ja) 1988-05-27 1991-10-09 セントカー・インコーポレーテツド 抗体産生物の凍結乾燥した配合物
AU686113B2 (en) 1992-09-16 1998-02-05 Scripps Research Institute, The Human neutralizing monoclonal antibodies to respiratory syncytial virus
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
CA2226575C (fr) 1995-07-27 2011-10-18 Genentech, Inc. Formulation de proteine lyophilisee isotonique et stable
ZA966075B (en) 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
ES2148799T3 (es) 1995-09-18 2000-10-16 Intracel Corp Anticuerpos monoclonales neutralizantes contra virus sincitial respiratorio.
US20070059302A1 (en) 1997-04-07 2007-03-15 Genentech, Inc. Anti-vegf antibodies
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
WO2000032634A1 (fr) 1998-12-01 2000-06-08 Protein Design Labs, Inc. Anticorps anti-interferon gamma humanises
EP1820516B1 (fr) 1999-02-22 2013-07-24 University of Connecticut Nouvelles formulations de facteur VIII sans albumine
DE60041393D1 (de) 1999-03-11 2009-03-05 Schering Corp Cytokine aus säugetieren, verwandte reagenzien und verfahren
DE60038304T3 (de) 1999-09-09 2017-04-06 Merck Sharp & Dohme Corp. Interleukin-12 p40 und interleukin-b30. kombinationen davon. antikörper. verwendungen in pharmazeutische zusammensetzungen
US7090847B1 (en) 1999-09-09 2006-08-15 Schering Corporation Mammalian cytokines; related reagents and methods
WO2001030393A2 (fr) 1999-10-22 2001-05-03 Ludwig Institute For Cancer Research Procedes permettant de reduire les effets des cancers exprimant l'antigene a33 a l'aide d'immunoglobulines specifiques de l'antigene a33
US20050175986A1 (en) 2000-05-09 2005-08-11 Smit Kline Beecham Corporation Human monoclonal antibody
DE60139944D1 (de) 2000-10-12 2009-10-29 Genentech Inc Niederviskose konzentrierte proteinformulierungen
US6818216B2 (en) 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
EP1801123A3 (fr) 2000-12-28 2007-11-21 Altus Pharmaceuticals Inc. Cristaux d'anticorps complets et de fragments correspondants et leurs procédés de fabrication et d'utilisation
EP1345968A2 (fr) 2000-12-28 2003-09-24 Altus Biologics Inc. Cristaux d'anticorps entiers et fragments d'anticorps et methodes de fabrication et d'utilisation associees
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
JP2005500304A (ja) 2001-06-21 2005-01-06 アルタス バイオロジックス インコーポレイテッド 球状タンパク質粒子およびそれらの作製方法および使用方法
TR201809678T4 (tr) 2001-06-26 2018-07-23 Amgen Fremont Inc Opgl ye karşi antikorlar.
ATE454137T1 (de) 2001-07-25 2010-01-15 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
US20030138417A1 (en) 2001-11-08 2003-07-24 Kaisheva Elizabet A. Stable liquid pharmaceutical formulation of IgG antibodies
DE10207178A1 (de) 2002-02-19 2003-09-04 Novosom Ag Komponenten für die Herstellung amphoterer Liposomen
CA2476934C (fr) 2002-02-27 2009-06-16 Immunex Corporation Composition stabilisee du fragment fc et du recepteur tnf comprenant de l'arginine
US20070134247A9 (en) 2002-04-12 2007-06-14 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
DE60334303D1 (de) 2002-07-03 2010-11-04 Tasuku Honjo Immunpotenzierende zusammensetzungen
WO2004007520A2 (fr) 2002-07-12 2004-01-22 Medarex, Inc. Procedes et compositions visant a prevenir la degradation oxydative de proteines
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
JP4416653B2 (ja) 2002-08-21 2010-02-17 ファルマシア コーポレーション 2つのチャンバーを有するバイアルに収容された注射用医薬懸濁液
US20040091490A1 (en) 2002-08-28 2004-05-13 Robert Johnson Stable pH optimized formulation of a modified antibody
AU2003293543A1 (en) 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
US7563869B2 (en) 2003-01-23 2009-07-21 Ono Pharmaceutical Co., Ltd. Substance specific to human PD-1
US20040219150A1 (en) 2003-02-06 2004-11-04 Cua Daniel J. Uses of mammalian cytokine; related reagents
CN103040732B (zh) 2003-02-10 2015-04-01 伊兰药品公司 免疫球蛋白制剂及其制备方法
ATE440864T1 (de) 2003-03-10 2009-09-15 Schering Corp Verwendung von il-23-antagonisten; verwandte reagenzien
PT1610820E (pt) 2003-04-04 2010-12-16 Novartis Ag Formulações de elevada concentração de anticorpos e proteínas
KR20060080535A (ko) 2003-05-14 2006-07-10 이뮤노젠 아이엔씨 약물 콘쥬게이트 조성물
US7410483B2 (en) 2003-05-23 2008-08-12 Novare Surgical Systems, Inc. Hand-actuated device for remote manipulation of a grasping tool
WO2005035574A1 (fr) 2003-10-09 2005-04-21 Chugai Seiyaku Kabushiki Kaisha Solution stabilisee a concentration elevee en igm
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
PE20090047A1 (es) 2003-11-10 2009-01-26 Schering Corp Anticuerpo recombinante humanizado anti-interleuquina 10
DE10355904A1 (de) 2003-11-29 2005-06-30 Merck Patent Gmbh Feste Formen von anti-EGFR-Antikörpern
WO2005063291A1 (fr) 2003-12-25 2005-07-14 Kirin Beer Kabushiki Kaisha Preparation medicamenteuse aqueuse stable contenant un anticorps
ES2689328T3 (es) 2004-01-07 2018-11-13 Novartis Vaccines And Diagnostics, Inc. Anticuerpo monoclonal M-CSF-específico y usos del mismo
EP1713502A1 (fr) 2004-02-12 2006-10-25 MERCK PATENT GmbH Formulations liquides fortement concentrees d'anticorps anti-egfr
CN1942201B (zh) 2004-02-17 2012-06-20 先灵公司 调节il-23活性的方法;相关试剂
ATE531388T1 (de) 2004-03-24 2011-11-15 Abbott Biotherapeutics Corp Verwendung von anti-alpha5beta1-antikörpern zur hemmung der krebszellproliferation
AU2005249360B2 (en) 2004-04-12 2011-07-21 Medimmune, Llc Anti-IL-9 antibody formulations and uses thereof
WO2005120571A2 (fr) 2004-06-07 2005-12-22 Ramot At Tel Aviv University Ltd. Procede d'immunisation passive contre des maladies ou des troubles caracterise(e)s par agregation amyloide a risque diminue de neuroinflammation
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
AU2005290250A1 (en) 2004-07-30 2006-04-06 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
US9114069B2 (en) 2004-08-25 2015-08-25 Aegis Therapeutics, Llc Antibacterial compositions for drug administration
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US20080057070A1 (en) 2004-11-04 2008-03-06 Chiron Corporation Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
PA8661401A1 (es) 2005-01-28 2006-09-08 Wyeth Corp Formulaciones del liquido polipeptido estabilizado
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
DOP2006000029A (es) 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
EP1865986B1 (fr) 2005-03-08 2016-02-17 Pfizer Products Inc. Compositions d'anticorps anti-ctla-4
ES2407468T3 (es) 2005-04-18 2013-06-12 Yeda Research And Development Company Limited Formulaciones de anticuerpos anti-hepatitis B (HBV) estabilizadas
PL1874818T3 (pl) 2005-04-22 2011-09-30 Lilly Co Eli Przeciwciała swoiste wobec TGF-beta 1
EP3530736A3 (fr) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Anticorps monoclonaux humains pour mort programmée 1 (pd-1) et procédés de traitement du cancer à l'aide d'anticorps anti-pd-1 seuls ou combinés à d'autres formulations immunothérapeutiques
EP1891110A2 (fr) 2005-06-07 2008-02-27 Esbatech AG ANTICORPS STABLES ET SOLUBLES INHIBANT LE TNF-alpha
WO2006133486A1 (fr) 2005-06-14 2006-12-21 The Macfarlane Burnet Institute For Medical Research And Public Health Limited Structures cristallines et modeles de complexes fc/recepteurs fc et utilisations de ces derniers
BRPI0611800A2 (pt) 2005-06-15 2008-12-09 Schering Corp formulaÇço estÁvel de anticorpo
CA2613818C (fr) 2005-06-30 2013-08-27 Centocor, Inc. Anticorps anti-il-23, compositions, methodes et utilisations
CA2615731A1 (fr) 2005-07-29 2007-02-08 Amgen Inc. Formulations inhibant l'agregation de proteines
WO2007019232A2 (fr) 2005-08-03 2007-02-15 Immunogen, Inc. Formulations d'immunoconjugué
SI1937721T1 (sl) 2005-08-25 2010-11-30 Lilly Co Eli Anti il protitelesa
ME02705B (fr) 2005-08-31 2017-10-20 Merck Sharp & Dohme Anticorps anti-il-23 obtenus par genie genetique
AU2006291005A1 (en) 2005-09-12 2007-03-22 Novimmune S.A. Anti-CD3 antibody formulations
KR101363777B1 (ko) 2005-09-30 2014-02-14 메디뮨 리미티드 인터루킨―13 항체 조성물
JP5231810B2 (ja) 2005-12-28 2013-07-10 中外製薬株式会社 抗体含有安定化製剤
SI3219328T1 (sl) 2005-12-29 2020-10-30 Janssen Biotech, Inc. Človeška protitelesa proti-IL-23, sestavki, postopki in uporabe
JP2009525986A (ja) 2006-02-03 2009-07-16 メディミューン,エルエルシー タンパク質製剤
CA2647111A1 (fr) 2006-03-28 2007-10-04 F. Hoffmann-La Roche Ag Formulation d'anticorps monoclonal humain anti-igf-1r
CA2649538C (fr) 2006-04-21 2014-06-03 Yatin Gokarn Agents de tamponnage pour formulations biopharmaceutiques
SMP200800064B (it) 2006-04-21 2009-11-06 Novartis Ag Composizioni farmaceutiche di anticorpi anti-cd40 antagonista
JP2009540018A (ja) 2006-06-13 2009-11-19 ザイモジェネティクス, インコーポレイテッド Il−17およびil−23アンタゴニストならびにその使用方法
CA2665567C (fr) 2006-10-06 2012-07-03 Amgen Inc. Formulations stables
US7705132B2 (en) 2006-10-20 2010-04-27 Amgen Inc. Stable polypeptide formulations
EP2684895A1 (fr) 2006-10-27 2014-01-15 AbbVie Biotechnology Ltd Anticorps anti-hTNfalpha cristallins
WO2008068246A1 (fr) 2006-12-05 2008-06-12 Crucell Holland B.V. Formulations liquides d'anticorps anti-rage
AR064333A1 (es) 2006-12-14 2009-04-01 Schering Corp Anticuerpo anti-tslp de diseno
EP2129401B8 (fr) 2006-12-21 2020-01-15 Amgen Inc. Formulations tamponnées stables contenant des polypeptides
JP5419709B2 (ja) 2007-01-09 2014-02-19 ワイス・エルエルシー 抗il−13抗体製剤およびその使用
TWI426918B (zh) 2007-02-12 2014-02-21 Merck Sharp & Dohme Il-23拮抗劑於治療感染之用途
HUE042172T2 (hu) 2007-02-23 2019-06-28 Merck Sharp & Dohme Genetikailag elõállított anti-il-23P19 antitestek
CN103396489A (zh) 2007-02-23 2013-11-20 默沙东公司 工程改造的抗IL-23p19抗体
CA2681752A1 (fr) 2007-03-29 2008-10-09 Abbott Laboratories Anticorps anti-1l-12 humains cristallins
KR101540823B1 (ko) 2007-03-30 2015-07-30 메디뮨 엘엘씨 항체 제제
US20090208492A1 (en) 2007-06-14 2009-08-20 Elan Pharmaceuticals, Inc. Lyophilized Immunoglobulin Formulations and Methods of Preparation
CA2690382A1 (fr) 2007-06-14 2008-12-24 Biogen Idec Ma Inc. Formulations d'anticorps
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
AU2008269086B2 (en) 2007-06-25 2014-06-12 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
UA107557C2 (xx) 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
US20100286038A1 (en) 2007-09-21 2010-11-11 Valentyn Antochshuk Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same
EP2205276A4 (fr) 2007-09-28 2012-08-15 Janssen Biotech Inc Anticorps anti-il-12/23p40, épitopes, formulations, compositions, procédés et utilisations
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
EP2225275A4 (fr) 2007-11-28 2013-04-03 Medimmune Llc Formulation de protéine
WO2009080541A1 (fr) 2007-12-21 2009-07-02 F. Hoffmann-La Roche Ag Formulation d'anticorps
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
EP2240156A2 (fr) 2007-12-28 2010-10-20 BioInvent International AB Composition contenant des anticorps employee au traitement des maladies du système cardiovasculaire associé avec l'arteriosclerose
EP2249801A2 (fr) 2008-02-07 2010-11-17 Amgen Inc. Compositions protéiniques stabilisées
PT2242773T (pt) 2008-02-11 2017-09-15 Cure Tech Ltd Anticorpos monoclonais para o tratamento de tumores
WO2009120684A1 (fr) 2008-03-25 2009-10-01 Medimmune, Llc Formulation d’anticorps
WO2009126688A2 (fr) 2008-04-09 2009-10-15 Genentech, Inc. Compositions et procédés nouveaux pour le traitement de maladies de nature immunitaire
EP2297209A4 (fr) 2008-06-03 2012-08-01 Abbott Lab Immunoglobulines à deux domaines variables et leurs utilisations
US8460886B2 (en) 2008-07-04 2013-06-11 Ono Pharmaceutical Co., Ltd. Use of an efficacy marker for optimizing therapeutic efficacy of an anti-human PD-1 antibody on cancers
WO2010027766A1 (fr) 2008-08-27 2010-03-11 Schering Corporation Formulations lyophilisées d'anticorps anti-il-23p19 modifiés
SI2331090T1 (en) 2008-09-19 2018-04-30 Pfizer Inc. Stable liquid antibody formulation
RU2481824C2 (ru) 2008-10-29 2013-05-20 Аблинкс Н.В Препараты однодоменных антигенсвязывающих молекул
WO2010062372A2 (fr) * 2008-11-03 2010-06-03 President And Fellows Of Harvard College Procédés de modulation de nf-kb mettant en oeuvre des gibbérellines
KR20110097772A (ko) 2008-11-17 2011-08-31 제넨테크, 인크. 생리적 조건하에 거대분자의 응집을 감소시키는 방법 및 제제
WO2010069858A1 (fr) 2008-12-19 2010-06-24 F. Hoffmann-La Roche Ag Composition pharmaceutique
WO2010100200A2 (fr) 2009-03-05 2010-09-10 Novartis Ag Préparation d'anticorps lyophilisée
PE20120359A1 (es) 2009-03-06 2012-04-13 Genentech Inc Formulacion con anticuerpo
CN102413839A (zh) 2009-03-06 2012-04-11 医学免疫有限责任公司 人源化抗cd19抗体制剂
EP2230312A1 (fr) 2009-03-19 2010-09-22 Helmholtz-Zentrum für Infektionsforschung GmbH Composé de sonde pour détecter et isoler les enzymes et supports et procédés d'utilisation associés
US20100278822A1 (en) 2009-05-04 2010-11-04 Abbott Biotechnology, Ltd. Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
US9155745B2 (en) 2009-06-16 2015-10-13 Universite De Geneve Bevacizumab formulations with lower aggregation propensity, comprising corticosteroid anti-inflammatory drugs
MX2011013722A (es) 2009-06-18 2012-05-08 Wyeth Llc Formulaciones liofilizadas para inmunofarmaceuticos modulares pequeños.
WO2011008770A2 (fr) 2009-07-14 2011-01-20 Biogen Idec Ma Inc. Procédés pour l'inhibition de la formation de couleur jaune et du peroxyde dans une composition
WO2011017070A1 (fr) 2009-07-28 2011-02-10 Merck Sharp & Dohme Corp. Procédés de production de formulations pharmaceutiques lyophilisées à concentration élevée
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
WO2011024862A1 (fr) 2009-08-31 2011-03-03 三洋化成工業株式会社 Stabilisateur de solution aqueuse de protéines, solution aqueuse de protéines et détergent liquide contenant tous deux le stabilisateur, et méthode de stabilisation de protéines utilisant le stabilisateur
IN2015DN02826A (fr) 2009-09-03 2015-09-11 Merck Sharp & Dohme
WO2011028962A1 (fr) 2009-09-04 2011-03-10 Xoma Technology Ltd. Coformulations d’anticorps
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
DK2478005T3 (en) 2009-09-15 2015-02-16 Ajinomoto Althea Inc Protein a crystals and cross bound crystals and methods of use thereof
EP3594356A1 (fr) 2009-11-04 2020-01-15 Merck Sharp & Dohme Corp. Anticorps anti-tslp modifies
CN107095846A (zh) 2009-12-21 2017-08-29 霍夫曼-拉罗奇有限公司 抗体配制剂
US20110158987A1 (en) 2009-12-29 2011-06-30 F. Hoffmann-Laroche Ag Novel antibody formulation
US20120294866A1 (en) 2010-01-19 2012-11-22 F. Hoffmann-La Roche Ag Pharmaceutical formulation for proteins
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
US8513236B2 (en) 2010-02-03 2013-08-20 Laurus Labs Private Limited Pterostilbene cocrystals
KR20130031247A (ko) 2010-03-17 2013-03-28 애보트 리서치 비.브이. 항―신경 성장 인자(ngf) 항체 조성물
BR112012027828A2 (pt) 2010-05-03 2016-08-09 Genentech Inc composição de matéria, artigo de fabricação e método de redução da viscosidade de uma formulação contendo proteína e de preparação de uma formulação aquosa contendo proteína
EP2590971A4 (fr) 2010-06-17 2014-12-10 Fuzians Biomedicals Inc Composés utiles en tant qu'agents antiviraux, compositions, et procédés d'utilisation
EP2399604A1 (fr) 2010-06-25 2011-12-28 F. Hoffmann-La Roche AG Nouvelle formulation d'anticorps
FR2962908A1 (fr) 2010-07-20 2012-01-27 Lfb Biotechnologies Formulation d'anticorps anti-cd20
WO2012018538A2 (fr) 2010-07-26 2012-02-09 Schering Corporation Bio-essais pour la détermination de la modulation de pd-1
MX366337B (es) 2010-10-06 2019-07-05 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r).
WO2012076670A2 (fr) 2010-12-10 2012-06-14 Novartis Ag Formulation d'anticorps
US9145457B2 (en) 2011-03-25 2015-09-29 Amgen Inc. Sclerostin antibody crystals and formulations thereof
WO2012135408A1 (fr) 2011-03-31 2012-10-04 Merck Sharp & Dohme Corp. Formulations stables d'anticorps dirigés contre le récepteur humain pd-1 de la mort programmée et traitements associés
BR112013025845A2 (pt) 2011-04-07 2018-09-04 Glaxosmithkline Llc formulações com viscosidade reduzida
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
JP6176849B2 (ja) 2011-07-19 2017-08-09 中外製薬株式会社 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
US9512073B2 (en) 2011-10-27 2016-12-06 Massachusetts Institute Of Technology Amino acid-, peptide-and polypeptide-lipids, isomers, compositions, and uses thereof
KR102063028B1 (ko) 2012-01-23 2020-01-07 리제너론 파아마슈티컬스, 인크. 항-ang2 항체를 함유하는 안정화된 제형
KR20160105535A (ko) 2012-03-07 2016-09-06 카딜라 핼쓰캐어 리미티드 TNF-α 항체의 약제학적 제형
CN104204898B (zh) 2012-04-03 2017-12-15 圣安德鲁斯大学董事会 光片光学系统
CN109206516A (zh) 2012-05-03 2019-01-15 勃林格殷格翰国际有限公司 抗IL-23p19抗体
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
JP2015517306A (ja) 2012-05-11 2015-06-22 ノバルティス アーゲー モノクローナル抗体の精製のための結晶化方法
US9803010B2 (en) 2012-06-27 2017-10-31 Merck Sharp & Dohme Corp. Crystalline anti-human IL-23p19 antibodies
SG11201407420RA (en) * 2012-07-04 2015-02-27 Hoffmann La Roche Covalently linked antigen-antibody conjugates
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
WO2014031718A1 (fr) 2012-08-23 2014-02-27 Merck Sharp & Dohme Corp. Formulations stables d'anticorps contre la tslp
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
WO2014078627A1 (fr) 2012-11-19 2014-05-22 Merck Sharp & Dohme Corp. Formulations liquides pour des protéines de fusion tnfr:fc
WO2014093206A1 (fr) 2012-12-13 2014-06-19 Merck Sharp & Dohme Corp. Granulés sphériques lyophilisés d'anticorps anti-il-23
US9700633B2 (en) 2013-01-28 2017-07-11 Jenkem Technology Co., Ltd., Tianjin Branch Conjugates of water soluble polymer-amino acid oligopeptide-drug, preparation method and use thereof
HK1220698A1 (zh) 2013-03-13 2017-05-12 Seattle Genetics, Inc. 环糊精和抗体药物偶联物制剂
WO2014165422A1 (fr) 2013-04-02 2014-10-09 Merck Sharp & Dohme Corp. Test immunohistochimique pour détecter l'expression du ligand de mort programmée 1 (pd-l1) dans un tissu tumoral
DK3024484T3 (en) 2013-07-23 2018-10-08 Novaliq Gmbh STABILIZED ANTIBODY COMPOSITIONS
TWI649308B (zh) 2013-07-24 2019-02-01 小野藥品工業股份有限公司 喹啉衍生物
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
RS64268B1 (sr) 2013-09-20 2023-07-31 Bristol Myers Squibb Co Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora
DK3049441T3 (da) 2013-09-27 2020-02-03 Hoffmann La Roche Anti-PDL1-antistofformuleringer
WO2015057541A1 (fr) 2013-10-16 2015-04-23 Merck Sharp & Dohme Corp. Procédé d'obtention de formulations de vaccin séchées thermostables
RU2589691C2 (ru) 2014-06-16 2016-07-10 Общество с ограниченной ответственностью "Промоген-МАТ" Стабильная композиция антитела, специфически связывающегося с her2 рецепторами, и способ ее получения
WO2015196091A1 (fr) 2014-06-20 2015-12-23 Reform Biologics, Llc Composés excipient réduisant la viscosité pour formulations à base de protéines
WO2016011357A1 (fr) 2014-07-18 2016-01-21 Advaxis, Inc. Combinaison d'un antagoniste de pd-1 et d'un vaccin à base de listeria pour le traitement du cancer
CN105296433B (zh) 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
RS63364B1 (sr) 2014-08-11 2022-07-29 Acerta Pharma Bv Terapeutske kombinacije btk inhibitora, pd-1 inhibitora i/ili pd-l1 inhibitora
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
CA2957722C (fr) 2014-08-19 2022-05-31 Merck Sharp & Dohme Corp. Anticorps anti-tigit
EP3186281B1 (fr) 2014-08-28 2019-04-10 Halozyme, Inc. Thérapie combinée associant une enzyme dégradant le hyaluronane et un inhibiteur des postes de contrôle immunitaire
WO2016035006A1 (fr) 2014-09-01 2016-03-10 Dr. Reddy’S Laboratories Limited Nouveaux analogues de nucléotides, procédé de préparation de sofosbuvir et de ses analogues, nouvelles formes de sofosbuvir de dispersion solide de sofosbuvir
CN106999583A (zh) 2014-11-17 2017-08-01 豪夫迈·罗氏有限公司 包含ox40结合激动剂和pd‑1轴结合拮抗剂的组合疗法
EP3233918A1 (fr) 2014-12-19 2017-10-25 Novartis AG Polythérapies
US20170360929A1 (en) 2014-12-23 2017-12-21 Pfizer Inc. Stable aqueous antibody formulation for anti tnf alpha antibodies
AR103268A1 (es) 2014-12-23 2017-04-26 Bristol Myers Squibb Co Anticuerpos contra tigit
JP2018502123A (ja) 2015-01-20 2018-01-25 イミューンエクサイト, インコーポレイテッド 癌免疫療法のための組成物及び方法
AR103726A1 (es) 2015-02-27 2017-05-31 Merck Sharp & Dohme Cristales de anticuerpos monoclonales anti-pd-1 humanos
KR20240064733A (ko) 2015-03-04 2024-05-13 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
US20180044418A1 (en) * 2015-03-20 2018-02-15 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and vorinostat for treating cancer
ES2820768T3 (es) 2015-04-03 2021-04-22 Xoma Technology Ltd Tratamiento del cáncer usando inhibidores de TGF-beta y PD-1
HRP20201334T1 (hr) 2015-04-17 2020-11-27 Bristol-Myers Squibb Company Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba
EP3288980B1 (fr) 2015-04-28 2021-03-10 Bristol-Myers Squibb Company Traitement du mélanome pd-l1 positif à l'aide d'un anticorps anti-pd-1
EP3302501B1 (fr) 2015-05-29 2021-09-22 Merck Sharp & Dohme Corp. Association d'un antagoniste du pd-1 et d'un oligonucléotide cpg du type c pour le traitement du cancer
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
WO2017009813A1 (fr) * 2015-07-16 2017-01-19 Laurus Labs Private Limited Nouveaux co-cristaux de caféine et leur formes polymorphes
CN114853891A (zh) 2015-07-22 2022-08-05 索伦托药业有限公司 与lag3结合的抗体治疗剂
BR112018000366A2 (pt) 2015-08-07 2018-09-11 Pieris Pharmaceuticals Gmbh polipeptídeo de fusão, muteína de lipocalina, molécula de ácido nucleico, célula hospedeira, métodos de produção de um polipeptídeo de fusão, para inibir simultaneamente os pontos de controle imunes, para aumentar a atividade celular de linfócitos antitumorais e para interferir com a ligação do lag-3 humano e uso do polipeptídeo de fusão
CN115925931A (zh) 2015-08-14 2023-04-07 默沙东公司 抗tigit抗体
UA125747C2 (uk) * 2015-09-01 2022-06-01 Фьост Вейв Байо, Інк. Способи та композиції для лікування станів, пов'язаних із аномальною запальною відповіддю
RU2760582C2 (ru) 2015-09-02 2021-11-29 Иммутеп С.А.С. Анти-LAG-3 антитела
CA2998589A1 (fr) 2015-09-14 2017-03-23 Compass Therapeutics Llc Compositions et methodes de traitement du cancer au moyen de l'antagonimisme du parcours cd155/tigit et tgf-beta
US9995753B2 (en) 2015-09-25 2018-06-12 Merck Sharp & Dohme Corp. Anti-pembrolizumab antibodies
EP3357508A4 (fr) 2015-09-28 2019-04-24 Suzhou Suncadia Biopharmaceuticals Co., Ltd. Préparation pharmaceutique d'anticorps anti-pd-1 stable et application de celle-ci dans un médicament
US20170097333A1 (en) 2015-09-28 2017-04-06 Merck Sharp & Dohme Corp. Cell based assay to measure the t-cell stimulating capacity of anti-lag3 antibodies and other agents
PT3356413T (pt) 2015-10-01 2022-04-04 Potenza Therapeutics Inc Proteínas de ligação a antigénio anti-tigit e métodos de utilização das mesmas
PL3368572T5 (pl) 2015-10-02 2026-07-20 Les Laboratoires Servier Przeciwciała anty-PD-1 oraz kompozycje
JO3555B1 (ar) 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
JP7027321B2 (ja) 2015-11-03 2022-03-01 ヤンセン バイオテツク,インコーポレーテツド 抗cd38抗体の皮下製剤及びその使用
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
EP3394099A4 (fr) 2015-12-22 2019-11-27 Merck Sharp & Dohme Corp. Formulations d'anticorps anti-il-10 modifiés
ES2904593T3 (es) 2016-01-21 2022-04-05 Pfizer Anticuerpos monoespecíficos y biespecíficos para la variante III del receptor del factor de crecimiento epidérmico y CD3 y sus usos
AR107483A1 (es) 2016-01-29 2018-05-02 Hanmi Pharm Ind Co Ltd Conjugado de enzimas terapéuticas
JP2019514889A (ja) 2016-04-25 2019-06-06 メディミューン,エルエルシー 抗pd−l1および抗ctla−4抗体の共製剤を含む組成物
EP3848393A1 (fr) 2016-05-18 2021-07-14 Boehringer Ingelheim International GmbH Molécules d'anticorps pour le traitement du cancer
CA3026151A1 (fr) 2016-06-14 2017-12-21 Xencor, Inc. Anticorps inhibiteurs de points de controle bispecifiques
EP3541413A2 (fr) 2016-11-21 2019-09-25 Polpharma Biologics S.A. Formulations pharmaceutiques aqueuses
BR112019011900A2 (pt) 2016-12-23 2019-11-26 Serum Institute Of India Private Limited métodos melhorados para aumentar a produtividade de anticorpos na cultura de células de mamíferos e minimizar a agregação durante os processos downs-tream, processos de formulação, e formulações de anticorpos estáveis obtidas dos mesmos
TWI911431B (zh) 2017-03-01 2026-01-11 英商梅迪繆思有限公司 抗rsv單株抗體配製物
JP2020509025A (ja) 2017-03-01 2020-03-26 メドイミューン・リミテッドMedImmune Limited モノクローナル抗体製剤
EP3601355A1 (fr) 2017-03-31 2020-02-05 Bristol-Myers Squibb Company Procédés de traitement de tumeur
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
SG11201909941QA (en) 2017-05-02 2019-11-28 Merck Sharp & Dohme Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
CN110913906A (zh) 2017-05-02 2020-03-24 默沙东公司 抗lag3抗体的制剂和抗lag3抗体与抗pd-1抗体的共制剂
CA3060695A1 (fr) 2017-05-02 2018-11-08 Merck Sharp & Dohme Corp. Formulations stables d'anticorps anti-ctla4 seuls et en combinaison avec des anticorps anti-recepteur de mort programmee 1 (pd-1) et leurs procedes d'utilisation
US10646569B2 (en) 2017-05-16 2020-05-12 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
JP7301002B2 (ja) 2017-05-30 2023-06-30 ブリストル-マイヤーズ スクイブ カンパニー 抗lag-3抗体または抗lag-3抗体および抗pd-1もしくは抗pd-l1抗体を含む組成物
WO2018222718A1 (fr) 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Traitement de tumeurs positives pour lag-3
EP3678700B1 (fr) 2017-09-05 2024-06-19 Merck Sharp & Dohme LLC Composés pour la réduction de la viscosité de formulations biologiques
MX2020009824A (es) 2018-07-25 2021-01-15 Alteogen Inc Nuevas variantes de hialuronidasa y composicion farmaceutica que comprende la misma.
KR20210038618A (ko) 2018-07-30 2021-04-07 샤이어-엔피에스 파마슈티칼즈, 인크. 재조합 인간 부갑상선 호르몬의 개선된 안정성을 위한 제형
MA54089A (fr) 2018-10-31 2022-02-09 Merck Sharp & Dohme Anticorps anti-pd-1 humain et procédés d'utilisation associés
WO2020096917A1 (fr) 2018-11-05 2020-05-14 Merck Sharp & Dohme Corp. Schéma posologique d'un anticorps anti-lag3 et polythérapie avec un anticorps anti-pd-1 pour le traitement du cancer
US20210380694A1 (en) 2018-11-07 2021-12-09 Merck Sharp & Dohme Corp. Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
JP7503056B6 (ja) 2018-11-07 2024-07-16 メルク・シャープ・アンド・ドーム・エルエルシー 抗lag3抗体および抗pd-1抗体の共-製剤
CN112203642B (zh) 2019-03-25 2025-03-07 阿特根公司 用于皮下注射的包含人透明质酸酶ph20变体和药物的药物组合物
JP2023504748A (ja) 2019-12-09 2023-02-06 ジェネンテック, インコーポレイテッド 抗pd-l1抗体製剤
US20230365692A1 (en) 2020-09-24 2023-11-16 Merck Sharp & Dohme Llc Stable formulations of programmed death receptor 1 (pd-1) antibodies and hyaluronidase variants and fragments thereof and methods of use thereof
PT4267105T (pt) 2020-12-28 2025-04-30 Bristol Myers Squibb Co Composições de anticorpos e métodos de utilização das mesmas

Also Published As

Publication number Publication date
KR102876292B1 (ko) 2025-10-28
CN120842406A (zh) 2025-10-28
JP7475341B2 (ja) 2024-04-26
CN113015748B (zh) 2025-12-12
AU2019369222B2 (en) 2026-04-16
JP2022512840A (ja) 2022-02-07
KR20210084561A (ko) 2021-07-07
WO2020092233A1 (fr) 2020-05-07
CN113015748A (zh) 2021-06-22
BR112021008122A8 (pt) 2023-01-31
EP3873941B1 (fr) 2026-07-01
EP3873941A1 (fr) 2021-09-08
AU2019369222A1 (en) 2021-05-27
BR112021008122A2 (pt) 2021-08-03
CA3116592A1 (fr) 2020-05-07
US12576159B2 (en) 2026-03-17
MX2021004928A (es) 2021-06-08
US20210317215A1 (en) 2021-10-14
US20260183412A1 (en) 2026-07-02
EP3873941A4 (fr) 2022-07-27

Similar Documents

Publication Publication Date Title
EP3873941A4 (fr) Anticorps anti-pd-1 humain et procédés d'utilisation associés
EP3797123A4 (fr) Anticorps anti-ox40 et procédés d'utilisation
MA52753A (fr) Anticorps anti-sirpa et leurs procédés d'utilisation
MA52091A (fr) Anticorps contre la protéine régulatrice de signal alpha et procédés d'utilisation
MA50956A (fr) Anticorps anti-cd137 et procédés d'utilisation correspondants
MA55025A (fr) Anticorps anti-trem2 et leurs procédés d'utilisation
MA53015A (fr) Anticorps anti-sirp-bêta1 et procédés d'utilisation associés
MA49512A (fr) Protéines de liaison à l'antigène anti-papillomavirus humain et leurs méthodés d'utilisation
MA46290A (fr) Anticorps contre la protéine régulatrice de signal alpha et procédés d'utilisation
EP3935155A4 (fr) Polypeptides effecteurs crispr-cas et procédés d'utilisation associés
EP3826641A4 (fr) Compositions d'anticorps anti-fcrn et leurs procédés d'utilisation
EP3731867A4 (fr) Anticorps anti-lrp5/6 et leurs procédés d'utilisation
EP3710589A4 (fr) Anticorps anti-c1s et procédés d'utilisation
EP4289862A4 (fr) Anticorps anti-b7-h3 humain et utilisation associée
EP3472200A4 (fr) Anticorps anti-myostatine et leurs procédés d'utilisation
EP3953385A4 (fr) Anticorps cd19 et leurs procédés d'utilisation
MA56455A (fr) Auto-injecteur et procédés d'utilisation associés
EP3873939A4 (fr) Anticorps anti-cd79b et récepteurs d'antigènes chimériques et leurs procédés d'utilisation
EP3740186A4 (fr) Dosette de produit d'hygiène et ses procédés d'utilisation
MA53328A (fr) Anticorps anti-siglec-5 et leurs procédés d'utilisation
EP3909063A4 (fr) Dosage multiplexé et ses procédés d'utilisation
EP3980067A4 (fr) Protéine de fusion anticorps-interleukine et procédés d'utilisation
EP3867271A4 (fr) Formulations d'anticorps anti-rsv et leurs procédés d'utilisation
EP3830128A4 (fr) Anticorps anti-mica/b qui bloquent l'élimination de mica/b et procédés d'utilisation
MA51207A (fr) Anticorps monoclonaux anti-trkb et leurs procédés d'utilisation